产品
编 号：F053802
分子式：C12H10NOPS
分子量：247.25
分子式：C12H10NOPS
分子量：247.25
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 117089-08-4
产品详情
生物活性：
FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-κB activity and induces cell apoptosis. FW1256 exerts potent anti-inflammatory effects and has the potential for cancer and cardiovascular disease treatment.
体内研究：
FW1256 (100 mg/kg; intraperitoneal injection; male C57BL/6 mice) treatment reduces IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.Animal Model:Male C57BL/6 mice (20-25 g, 6-10 weeks) injected with E. coli lipopolysaccharide (LPS)
Dosage:100 mg/kg
Administration:Intraperitoneal injection
Result:Reduced IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.
体外研究：
FW1256 (200 μM; 24.5 hours; AW264.7 cells) treatment significantly reduces IL-1β, COX-2 and iNOS mRNA and protein in LPS-stimulated RAW264.7 macrophages.FW1256 (200 μM; 24.5 hours; AW264.7 cells) treatment significantly reduces IL-1β, COX-2 and iNOS PROTE and protein in LPS-stimulated RAW264.7 macrophages.FW1256 concentration dependently decreases TNF-α (IC50 of 61.2 μM), IL-6 (IC50 of 11.7 μM), PGE2 (IC50 of 25.5 μM) and NO (IC50 of 34.6 μM) generation in LPS-stimulated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs) (IC50s of 414.9 μM, 300.2 μM, 4 μM and 9.5 μM for TNF-α, IL-6, PGE2 and NO, respectively) .FW1256 decreases NF-κB activation as evidenced by reduced cytosolic phospho-IκBα levels and reduces nuclear p65 levels in LPS-stimulated RAW264.7 macrophages treated with FW1256.
FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-κB activity and induces cell apoptosis. FW1256 exerts potent anti-inflammatory effects and has the potential for cancer and cardiovascular disease treatment.
体内研究：
FW1256 (100 mg/kg; intraperitoneal injection; male C57BL/6 mice) treatment reduces IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.Animal Model:Male C57BL/6 mice (20-25 g, 6-10 weeks) injected with E. coli lipopolysaccharide (LPS)
Dosage:100 mg/kg
Administration:Intraperitoneal injection
Result:Reduced IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.
体外研究：
FW1256 (200 μM; 24.5 hours; AW264.7 cells) treatment significantly reduces IL-1β, COX-2 and iNOS mRNA and protein in LPS-stimulated RAW264.7 macrophages.FW1256 (200 μM; 24.5 hours; AW264.7 cells) treatment significantly reduces IL-1β, COX-2 and iNOS PROTE and protein in LPS-stimulated RAW264.7 macrophages.FW1256 concentration dependently decreases TNF-α (IC50 of 61.2 μM), IL-6 (IC50 of 11.7 μM), PGE2 (IC50 of 25.5 μM) and NO (IC50 of 34.6 μM) generation in LPS-stimulated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs) (IC50s of 414.9 μM, 300.2 μM, 4 μM and 9.5 μM for TNF-α, IL-6, PGE2 and NO, respectively) .FW1256 decreases NF-κB activation as evidenced by reduced cytosolic phospho-IκBα levels and reduces nuclear p65 levels in LPS-stimulated RAW264.7 macrophages treated with FW1256.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备